Latest news and articles about Indian market from NEX English
Novo Nordisk has reported a significant increase of <strong>40%</strong> in sales of diabetes and weight loss medications in India last month due to substantial price reductions. This surge occurs despite the entry of generic GLP-1 drugs into the market.
India is witnessing a significant rise in cheap copies of the drug 'semaglutide', negatively affecting sales for Eli Lilly. This situation raises questions about the company's future as patent expirations approach.
Regulators in India have announced measures to simplify daily transaction settlements for foreign investors in the stock market, enhancing their participation. This initiative is part of broader efforts to stimulate economic activity and facilitate business operations.